Propafenone Hydrochloride Capsule, Extended Release
Product Images NDC 68462-408

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Propafenone Hydrochloride (NDC 68462-408). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lbl225mg60

Label for propafenone hydrochloride extended-release capsules USP, containing 225 mg strength. The label shows the active ingredient and dosage form, with a package quantity of 60 capsules. It includes the Glenmark Pharmaceuticals Inc. logo and is marked Rx Only. The label features storage instructions, manufacturer information, and a barcode.*

FDA Label Image

Lbl32560

Label for propafenone hydrochloride extended-release capsules USP, 325 mg strength. The label indicates a package size of 60 capsules. The product is labeled by Glenmark Pharmaceuticals Inc. The design includes dosage information, storage instructions, a barcode, and manufacturer details from Glenmark Pharmaceuticals Limited in India.*

FDA Label Image

Lbl425mg60

Label for Propafenone Hydrochloride Extended-Release Capsules USP, 425 mg strength. The label indicates the product contains 60 capsules for oral use. It is manufactured by Glenmark Pharmaceuticals Limited, India, and marketed by Glenmark Pharmaceuticals Inc., USA. The label includes storage and dosage instructions and a barcode.*

FDA Label Image

Structure (Structure)

Chemical structure of propafenone hydrochloride, showing its molecular arrangement with phenyl rings, an ether linkage, a hydroxyl group, and an amine side chain, along with the hydrochloride (HCl) component.*

FDA Label Image

Figure-1 (Figure 1)

A Kaplan-Meier survival curve chart showing the proportion of patients without an event over days up to 300, comparing placebo and three dose levels of propafenone hydrochloride extended-release capsules (225 mg, 325 mg, 425 mg, all bid). The chart includes patient risk numbers at various time points and indicates statistically significant differences (p-values) at week 39 (day 273). Annotations note patient closeout starting at week 39 and a specific event affecting the curve for the 325 mg dose group.*

FDA Label Image

Logo

FDA Label Image

Logo2

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.